Repeated sub-apnoeic doses of suxamethonium produce increased neuromuscular block in a hand muscle, measured by integrated electromyogram. The response to the initial dose varies widely between patients. More than 50% of patients showed evidence of non-depolarising block after one dose of suxamethonium. There was a variation between the response of the hand muscle and respiratory muscles.
REPEATED DOSES OF SUXAMETHONIUM Suxamethonium produces a rapid onset of profound but brief muscular relaxation in most patients. Gibb l , 3 in his comprehensive review discussed a number of side effects of the drug which are relative contraindications to its use. The most important ones are rises in the intraocular, intracranial and intragastric pressures, a rise in plasma potassium and postoperative muscle pains.
To minimise the rises in intraocular and intragastric pressure, it has become common practice to give a small dose of nondepolarising muscle relaxant about three minutes before the suxamethonium. 4 ,5 Paralysis can then be induced with reduced rises in pressure. The dose of suxamethonium must be increased from 1 mg to 1.5 mg/kg to achieve adequate relaxation. 6 More recently Baraka 7 has reported the use of a small dose of suxamethonium to avoid the side effects of a second larger dose. This has been termed a "self taming" dose. A review of the literatures. IQ suggests that repeated doses of suxamethonium produce a diminishing response, a so-called tachyphylaxis; but Khmelevskyll reported that repeated injections in the rabbit produced an enhanced degree of paralysis.
This paper reports the electromyographic response to repeated doses of 0.2 mg/kg of suxamethonium, the aim being to determine the optimal dose of suxamethonium following the initial self-taming dose in clinical practice.
MATERIAL
Children presenting for anaesthesia were accepted into the series without selection. The operations required brief and repeated periods of muscular relaxation, such as is often requested during inguinal and umbilical herniotomy. Anaesthesia was preceded by an appropriate dose either of papaveretum and scopolamine or atropine premedication; induced with thiopentone (5 mg/kg) and maintained by nitrous oxide and 1 % halothane. At least 10 minutes were allowed for the patient to become equilibrated with the halothane before the first dose of suxamethonium was given.
METHOD
A compound electromyogram (EM G) was obtained from the adductor pollicis muscle by ECG adhesive pickups. The forearm was immobilised in a splint, and the median nerve stimulated at the wrist by supramaxima! stimuli at 0.5 Hz and duration 0.2 m.sec. The integrated EMG I2 (lEMG) was allowed to stabilise for about five minutes before suxamethonium was given.
Suxamethonium was drawn into a syringe and diluted to give 0.2 mg/kg in 1.0 ml, ensuring accuracy of dosage. This was given through an indwelling needle, care being taken to flush in any solution remaining in the needle. A further 0.2 mg/kg was given to 10 patients four minutes after the first one, and to nine patients seven minutes after. Further doses at similar time intervals were given to some patients, and at the end of the series five patients were given 0.2 mg/kg followed by 1.0 mg/kg to find out whether this sequence was suitable for endotracheal intubation.
In some of the patients a burst of 10 Hz stimuli were given to the median nerve when the EMG had returned to the baseline, to detect whether "fade" was developing and hence nondepolarising block.
RESULTS
The effect of the second dose was consistently greater than the first, as shown in figures 1, 2, 3 and 4.
The amount of depression was measured by taking the control IEMG as 1000,:0 and electrical silence (no IEMG) as 0, and measuring the depression on this scale. The first and second doses at four minute intervals produced a mean depression of 0.56 ± 0.24 (standard deviation) and 0.79 ± 0.18. An analysis of variance produced an F value of 11.368 for 10 pairs of data, corresponding to 0.01 < p < 0.005.
For the seven minute interval the means were 0.44±0.22 and 0.66±0.13. The F value was 14.7875 for nine pairs of data, corresponding to p < 0.005.
A further analysis of variance between the individual results in each of the four and seven minute groups revealed no significant variation. The increased response to the second dose is therefore significant and constant.
In the five patients given 0.2 mg/kg followed by 1.0 mg/kg at intervals ranging from one to six minutes, a period of apnoea followed the second dose in each case. The duration of apnoea was 2.0, 2.5, 5.0, 2.0 and 3.5 minutes, this being sufficient to inflate the lungs with oxygen and intubate the patient.
Although the response to the second identical dose of suxamethonium was increased so predictably, further doses resulted in responses similar to that following the second dose. This was confirmed by repetition up to five times (Figures 1 and 2) .
In some patients the response increased progressively, reaching a maximum with the third dose (Figures 3, 4) . In others the response to the first dose was almost maximal, and subsequent doses produced a longer rather than a more profound paralysis ( Figure 5 ). It was noted that the intensity of the response to the initial 0.2 mg/kg was quite variable (Figures 1,  2, 3, 4, 5 ). This variability is seen also in respiratory muscles: in some patients respiratory paralysis almost to apnoea followed the first dose of suxamethonium while in others no obvious change occurred.
In 13 patients a burst of 10 Hz tetanus was given during the recovery phase from the first injection. In eight cases fade occurred, suggesting that a degree of non-depolarising block was developing ( Figure 5 ). In the remaining five there was no difference in the response to 0.5 or 10 Hz rates of stimulation (Figure 4) .
Plasma cholinesterase levels and dibucaine inhibition were estimated routinely on the subjects. No abnormality in the level or dibucaine number was detected. A "taming" dose of 0.2 mg/kg of suxamethonium does not decrease the response to a subsequent dose of 1.0 mg/kg in the way that a small dose of non-depolarising blocker does. The response to 1.0 mg/kg may be enhanced in the same way as the response to a second dose of 0.2 mg/kg. If a taming dose of suxamethonium is used to avoid undesirable side effects, a normal dose may therefore be used for subsequent intubation.
In the abductor pollicis brevis muscle evidence of non-depolarising block appeared in eight of 13 patients after a dose of suxamethonium.
The relationship between depression of adductor pollicis brevis and respiratory paralysis is variable. In three patients apnoea occurred with only 50070 depression of the electromyogram of the thumb muscle, but in the majority apnoea occurred only during part of the time during which the abductor was completely paralysed: this was observed in 22 patients. In seven patients apnoea did not occur even when the abductor was fully paralysed. This variability may be explained in part by the variations in per fusion of the hand. In patients with slow peripheral circulation due to cold or anxiety the intensity and duration of paralysis of the thumb would be expected to be less predictable than the well-per fused respiratory muscles. It is reasonable to recommend that care be taken when using the EMG as a paralysis monitor to ensure that the hand does not become cold.
